RecruitingPhase 3NCT06904287

Effectiveness of Magnesium in Addition to Prochlorperazine for the Treatment of Migraines

Evaluating the Effectiveness of Magnesium in Addition to Prochlorperazine for the Treatment of Migraines in the Emergency Department


Sponsor

Wake Forest University Health Sciences

Enrollment

100 participants

Start Date

Dec 16, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this research study is to find out if using magnesium in addition to prochlorperazine will help reduce your migraine pain.


Eligibility

Min Age: 18 Years

Inclusion Criteria4

  • Age ≥ 18 years or older
  • Able to provide informed consent
  • English speaking
  • Primary diagnosis of migraine. Patient with a previous diagnosis of migraine, who experience headaches with typical migraine features (e.g at least 2-3 of the following: recurrent, unilateral, pounding or throbbing in nature, associated with nausea), AND with a clinical exclusion of migraine mimics

Exclusion Criteria6

  • Pregnancy defined as a positive urine HCG
  • Allergy or sensitivity to study drug
  • Stated history of renal insufficiency
  • Documented history of myasthenia gravis
  • Consumption of study drug within 48 hours prior to enrollment
  • Previously enrolled in this trial during a different patient encounter

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMagnesium

Prochlorperazine 10 mg administered as an intravenous push over 2 minutes followed by magnesium 2 g administered as an intravenous bolus over a period of 20 minutes

DRUGPlacebo

Prochlorperazine 10 mg administered as an intravenous push over 2 minutes followed by placebo (normal saline)


Locations(1)

Advocate Christ Medical Center Emergency Department

Oak Lawn, Illinois, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06904287


Related Trials